Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Single-arm, Multicenter, Efficacy and Safety of 80mg Osimertinib in Patients With Leptomeningeal Metastases(LM) Associated With EGFR Mutation-positive Non-small Cell Lung Cancer(NSCLC)

NCT04563871 is registered in ClinicalTrials.gov with Sehhoon Park as lead sponsor.

NCT NCT04563871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04563871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Single-arm, Multicenter, Efficacy and Safety of 80mg Osimertinib in Patients With Leptomeningeal Metastases(LM) Associated With EGFR Mutation-positive Non-small Cell Lung Cancer(NSCLC)
Lead sponsor
Sehhoon Park
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2020
Completion date
October 25, 2023
Enrollment
73 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)